{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-021953","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.510902+00:00","generated_at":"2026-06-12T09:59:52.203958+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vaxart Q2 2023 net loss improves to $22.6M; norovirus Phase 2 data expected Q3","bullets":["Net loss of $22.6M ($0.16 per share) vs $29.4M ($0.23) in Q2 2022.","Revenue of $1.4M from Gates Foundation grant, compared to zero a year ago.","Cash and marketable securities $67.9M; cash runway extended into Q3 2024.","Positive preliminary topline data from Phase 2 bivalent norovirus vaccine; all primary endpoints met.","Topline data from GI.1 norovirus challenge study expected in Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-021953","json":"https://secwatch.observer/filing/0001437749-23-021953.json","markdown":"https://secwatch.observer/filing/0001437749-23-021953.md","text":"https://secwatch.observer/filing/0001437749-23-021953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774923021953/0001437749-23-021953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774923021953/vxrt20230506_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:59:52.203958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f66293812b88756649db96a3d20addc4ce48f86f","claim":"Vaxart, Inc. reported the quarter ended June 30, 2023 results: revenue $1.4 million, net income $22.6 million, EPS $0.16.","evidence_excerpt":"loss per share for the second quarter of 2023 was $0.16, compared to a net loss of $0.23 per share in the second quarter of 2022. ● Revenue for the second quarter of 2023 was $1.4 million, compared to no revenue in the second quarter of 2022. Revenue in the second quarter of 2023 was primarily from revenue recognized for work performed under Vaxart’s grant from","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774923021953/0001437749-23-021953-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$1.4 million"},{"label":"Net income","value":"$22.6 million"},{"label":"EPS","value":"$0.16"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}